Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Fosun Receives RMB12 Billion Syndicated Loan from 8 Banks to Jointly Promote Development of the Private Economy

On 16 January 2023, Shanghai Fosun High Technology (Group) Co., Ltd. (“Fosun High Technology”) and eight domestic banks held a syndicated loan signing ceremony at the Bund Finance Center, Shanghai. According to the agreement, Industrial and Commercial Bank of China, Agricultural Bank of China, Bank of China, China Construction Bank, an

Fosun International Receives Four Awards from Corporate Governance Asia

Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International win Asia’s Best CEO from Corporate Governance AsiaFosun International also receives Asia’s Best CSR and Best Corporate Communications AwardsOn 11 January 2023, the Corporate Governance Asia magazine presented the 12th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Execu

Fosun Foundation Partners with Fosun Pharma, and Genuine Biotech to Donate RMB100 Million Worth of Azvudine to 180 Counties in the Central and Western Rural Areas of China

On 9 January 2023, Fosun Foundation, togetherwith Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) and HenanGenuine Biotech Co., Ltd. (“Genuine Biotech”) announced a donation of RMB100 million worth of oral medication forCOVID-19 Azvudine to 180counties in the central and western rural areas of China in phases. WeProtect Rural Doctors, Rural D

Self-Paid Vaccination Service for Bivalent COVID-19 Vaccine COMIRNATY^® is Officially Provided in Hong Kong, Offering More Vaccine Options for People in Need

(HONG KONG, CHINA, January 6, 2023) - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) announced that the Group has provided bivalent COVID-19 Vaccine COMIRNATY^® (“Comirnaty bivalent vaccine”) to the private medical system in Hong Kong Special Administrative Region of the People’s Republic of China